Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:
“Today is a day I’ve been working toward for a long time.
Since losing my mom to colorectal cancer in 2009, I’ve dedicated my life to ensuring that other families experience different outcomes. As the CEO of the Colorectal Cancer Alliance, I’m proud to say we’re building something that would have amazed her.
Today at ASCO, we’re announcing KLEOS – an adaptive clinical trial platform, built in collaboration with the Global Coalition for Adaptive Research and backed by $7.5 million in seed donations.
Here’s why it matters: our clinical trial infrastructure hasn’t kept pace with the urgency patients are living every day. Trials are slow, siloed, and often don’t reach the patients who need them most. KLEOS changes that model entirely – allowing multiple therapies and combinations to be evaluated within a single master protocol framework, with real-time adaptive learning that accelerates what works and stops what doesn’t.
The result: faster regulatory pathways, lower RandD costs for pharma partners, and – most importantly – new treatment options for patients sooner. First enrollment is expected in Q1 2027.
We named it KLEOS, the ancient Greek word for glory, to honor those we’ve lost. Including my mom.
To our partners at GCAR, our staff, donors and every clinician and researcher in the Project Cure CRC Consortium: thank you for believing this was worth building. I guarantee you it is.”
Other articles featuring Michael Sapienza on OncoDaily.
